You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameZuclopenthixol
Accession NumberDB01624  (DB08919, DB08920)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Zuclopenthixol, also known as Zuclopentixol or Zuclopenthixolum, is an antipsychotic agent. Zuclopenthixol is a thioxanthene-based neuroleptic with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. Major brands of zuclopenthixol are Cisordinol, Acuphase, and Clopixol. This drug is a liquid. This compound belongs to the thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom. Known drug targets of zuclopenthixol include 5-hydroxytryptamine receptor 2A, D(1B) dopamine receptor, D(2) dopamine receptor, D(1A) dopamine receptor, and alpha-1A adrenergic receptor. It is known that zuclopenthixol is metabolized by Cytochrome P450 2D6. Zuclopenthixol was approved for use in Canada in 2011, but is not approved for use in the United States.

Structure
Thumb
Synonyms
cis-Clopenthixol
Zuclopenthixolum
Zuclopentixol
External Identifiers
  • N05AF05
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clopixol - Tab 10mgtablet10 mgoralHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Clopixol - Tab 25mgtablet25 mgoralHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Clopixol - Tab 40mgtablet40 mgoralHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Clopixol Acuphase - Liq Im 50mg/mlliquid50 mgintramuscularHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Clopixol Depot - Liq Im 200mg/mlliquid200 mgintramuscularHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Clopixol Depot - Liq Im 500mg/mlliquid500 mgintramuscularHoechst Marion Roussel Canada Inc.1995-12-311999-08-11Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Clopixol Depot 200mg/mlsolution200 mgintramuscularLundbeck Canada Inc1997-05-02Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Clopixol Depot 500mg/mlliquid500 mgintramuscularLundbeck Canada IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Clopixol Tablets 10mgtablet10 mgoralLundbeck Canada Inc1997-05-02Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Clopixol Tablets 25mgtablet25 mgoralLundbeck Canada Inc1997-05-02Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Clopixol Tablets 40mgtablet40 mgoralLundbeck Canada Inc1997-05-022003-03-24Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Clopixol-acuphase 50mg/mlsolution50 mgintramuscularLundbeck Canada Inc1997-05-02Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International Brands
NameCompany
AcuphaseH. Lundbeck A/S
Ciatyl-ZBayer Vital
CisordinolH. Lundbeck A/S
ClopixolH. Lundbeck A/S
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Zuclopenthixol acetate
Thumb
  • InChI Key: OXAUOBQMCDIVPQ-IOXNKQMXSA-N
  • Monoisotopic Mass: 442.148176515
  • Average Mass: 443.001
DBSALT000545
Zuclopenthixol decanoate
64053-00-5
Thumb
  • InChI Key: QRUAPADZILXULG-WKIKZPBSSA-N
  • Monoisotopic Mass: 554.273377027
  • Average Mass: 555.214
DBSALT000787
Zuclopenthixol dihydrochloride
Thumb
  • InChI Key: LPWNZMIBFHMYMX-MHKBYHAFSA-N
  • Monoisotopic Mass: 472.090967307
  • Average Mass: 473.887
DBSALT000546
Categories
CAS number53772-83-1
WeightAverage: 400.965
Monoisotopic: 400.137611829
Chemical FormulaC22H25ClN2OS
InChI KeyInChIKey=WFPIAZLQTJBIFN-DVZOWYKESA-N
InChI
InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5-
IUPAC Name
2-(4-{3-[(9Z)-2-chloro-9H-thioxanthen-9-ylidene]propyl}piperazin-1-yl)ethan-1-ol
SMILES
OCCN1CCN(CC\C=C2\C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiopyrans
Sub Class1-benzothiopyrans
Direct ParentThioxanthenes
Alternative Parents
Substituents
  • Thioxanthene
  • Diarylthioether
  • N-alkylpiperazine
  • Chlorobenzene
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • 1,2-aminoalcohol
  • Azacycle
  • Thioether
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed in the management of acute psychoses such as mania or schizophrenia. However, the use of zuclopenthixol acetate in psychiatric emergencies as an alternative to standard treatments (haloperidol, clotiapine, etc.) should be cautioned, since well executed and documented trials of zuclopenthixol acetate for this use have yet to be conducted. Zuclopenthixol acetate is not intended for long-term use.
PharmacodynamicsZuclopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.
Mechanism of actionZuclopenthixol is a typical antipsychotic neuroleptic drug of the thioxanthene class. It mainly acts by antagonism of D1 and D2 dopamine receptors. Zuclopenthixol also has high affinity for alpha1-adrenergic and 5-HT2 receptors. It has weaker histamine H1 receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors.
AbsorptionUpon reaching the body water phase, the decanoate ester is slowly released from the oil depot, which is resultantly hydrolyzed to the active substance, zuclopenthixol. The decanoate ester provides a means of slow release since zuclopenthixol itself is a short-acting drug.
Volume of distribution

20 L/kg.

Protein binding98-99%
Metabolism

The metabolism of zuclopenthixol is mainly by sulphoxidation, side chain N-dealkylation and glucuronic acid conjugation. The metabolites are devoid of pharmacological activity.

Route of eliminationPrimarily in the feces with approximately 10% in the urine.
Half life20 hours (range 12-28 hours) for the tablet form, 19 days for the depot form.
Clearance

approximately 0.9 L/min.

ToxicityAlthough there have not been any cases of overdosage reported, the symptoms are likely to be somnolence, coma, extrapyramidal symptoms, convulsions, hypotension, shock, or hyper- or hypothermia. Neuroleptic malignant syndrome may occur. Zuclopenthixol may potentiate anticholinergic effects of concurrent medications. Zuclopenthixol has a demonstrated antiemetic effect in animals, and may mask signs of toxicity due to other drug overdoses, or may mask symptoms of disease.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9443
Blood Brain Barrier+0.9676
Caco-2 permeable-0.5313
P-glycoprotein substrateSubstrate0.8762
P-glycoprotein inhibitor IInhibitor0.8736
P-glycoprotein inhibitor IIInhibitor0.7439
Renal organic cation transporterInhibitor0.5829
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6722
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorInhibitor0.7518
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8213
Ames testNon AMES toxic0.7617
CarcinogenicityNon-carcinogens0.9029
BiodegradationNot ready biodegradable0.9954
Rat acute toxicity2.8877 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6099
hERG inhibition (predictor II)Inhibitor0.7023
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral40 mg
Liquidintramuscular50 mg
Liquidintramuscular200 mg
Liquidintramuscular500 mg
Solutionintramuscular200 mg
Tabletoral10 mg
Tabletoral25 mg
Solutionintramuscular50 mg
Prices
Unit descriptionCostUnit
Clopixol Acuphase 50 mg/ml16.52USD ml
Clopixol Depot 200 mg/ml16.52USD ml
Clopixol 25 mg Tablet1.06USD tablet
Clopixol 10 mg Tablet0.42USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point~50http://www.lundbeck.com/upload/ca/en/files/pdf/product_monograph/Clopixol_PM_MKT_ctrl_148975_13SEPT2011_CLN_eng.pdf
water solubilityslighthttp://www.lundbeck.com/upload/ca/en/files/pdf/product_monograph/Clopixol_PM_MKT_ctrl_148975_13SEPT2011_CLN_eng.pdf
Predicted Properties
PropertyValueSource
Water Solubility0.0026 mg/mLALOGPS
logP4.46ALOGPS
logP4.22ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)8.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.71 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity127 m3·mol-1ChemAxon
Polarizability45.29 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (140 KB)
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. Pubmed
  2. Fond G, Macgregor A, Tamouza R, Hamdani N, Meary A, Leboyer M, Dubremetz JF: Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. Eur Arch Psychiatry Clin Neurosci. 2013 Jun 15. Pubmed
  3. Jayakody K, Gibson RC, Kumar A, Gunadasa S: Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev. 2012 Apr 18;4:CD000525. doi: 10.1002/14651858.CD000525.pub3. Pubmed
  4. Nielsen MK, Johansen SS: Simultaneous determination of 25 common pharmaceuticals in whole blood using ultra-performance liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 2012 Sep;36(7):497-506. doi: 10.1093/jat/bks054. Epub 2012 Jun 19. Pubmed
  5. Khalifa AE: Pro-oxidant activity of zuclopenthixol in vivo: differential effect of the drug on brain oxidative status of scopolamine-treated rats. Hum Exp Toxicol. 2004 Aug;23(9):439-45. Pubmed
  6. Hood S, Orr K, Bennett L, Davies S: Severe laryngeal dystonia in a patient receiving zuclopenthixol “Acuphase” and fluoxetine. Australas Psychiatry. 2010 Apr;18(2):174-6. doi: 10.3109/10398560903473686. Pubmed
  7. http://medicaid.alabama.gov/documents/2.0_Newsroom/2.4_Procurement/2.4.3_Pharm_Support_ITB/2.4.3_Antipsychotic_Agents_Class_Review_8-10-11.pdf
  8. http://www.mentalhealth.com/drug/p30-z03.html
External Links
ATC CodesN05AF05
AHFS Codes
  • 281608
PDB EntriesNot Available
FDA labelDownload (229 KB)
MSDSDownload (568 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Zuclopenthixol can be increased when it is combined with Abiraterone.
AclidiniumAclidinium may increase the anticholinergic activities of Zuclopenthixol.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Zuclopenthixol.
AmisulprideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Zuclopenthixol.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Zuclopenthixol.
AmphetamineZuclopenthixol may decrease the stimulatory activities of Amphetamine.
AprepitantThe serum concentration of Zuclopenthixol can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Atazanavir.
AzelastineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Zuclopenthixol.
BenzphetamineZuclopenthixol may decrease the stimulatory activities of Benzphetamine.
BoceprevirThe serum concentration of Zuclopenthixol can be increased when it is combined with Boceprevir.
Botulinum Toxin Type AZuclopenthixol may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BZuclopenthixol may increase the anticholinergic activities of Botulinum Toxin Type B.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
BromocriptineThe therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Bromocriptine.
BuprenorphineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Zuclopenthixol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Zuclopenthixol.
CarbamazepineThe serum concentration of Zuclopenthixol can be decreased when it is combined with Carbamazepine.
CathinoneZuclopenthixol may decrease the stimulatory activities of Cathinone.
Cimetropium BromideZuclopenthixol may increase the anticholinergic activities of Cimetropium Bromide.
CitalopramCitalopram may increase the QTc-prolonging activities of Zuclopenthixol.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Zuclopenthixol.
CobicistatThe serum concentration of Zuclopenthixol can be increased when it is combined with Cobicistat.
ConivaptanThe serum concentration of Zuclopenthixol can be increased when it is combined with Conivaptan.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zuclopenthixol.
DarunavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Darunavir.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Zuclopenthixol.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Zuclopenthixol.
DextroamphetamineZuclopenthixol may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Zuclopenthixol.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Zuclopenthixol.
DiltiazemThe serum concentration of Zuclopenthixol can be increased when it is combined with Diltiazem.
DofetilideDofetilide may increase the QTc-prolonging activities of Zuclopenthixol.
DonepezilDonepezil may increase the central neurotoxic activities of Zuclopenthixol.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Zuclopenthixol.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Zuclopenthixol.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Zuclopenthixol.
EluxadolineZuclopenthixol may increase the activities of Eluxadoline.
EnzalutamideThe serum concentration of Zuclopenthixol can be decreased when it is combined with Enzalutamide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zuclopenthixol.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Zuclopenthixol.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Zuclopenthixol.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Zuclopenthixol.
EthanolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zuclopenthixol.
FluconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Fluconazole.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Zuclopenthixol.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Zuclopenthixol.
FosamprenavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Fosamprenavir.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Zuclopenthixol.
GalantamineGalantamine may increase the central neurotoxic activities of Zuclopenthixol.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Glucagon recombinant.
GoserelinGoserelin may increase the QTc-prolonging activities of Zuclopenthixol.
HydrocodoneZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
IdelalisibThe serum concentration of Zuclopenthixol can be increased when it is combined with Idelalisib.
ImatinibThe serum concentration of Zuclopenthixol can be increased when it is combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Zuclopenthixol.
IndinavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Indinavir.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Zuclopenthixol.
IsavuconazoniumThe serum concentration of Zuclopenthixol can be increased when it is combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Zuclopenthixol.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Zuclopenthixol.
ItraconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Zuclopenthixol.
KetoconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Ketoconazole.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Zuclopenthixol.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Zuclopenthixol.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Zuclopenthixol.
LisdexamfetamineZuclopenthixol may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Zuclopenthixol.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zuclopenthixol.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Zuclopenthixol.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Zuclopenthixol.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Zuclopenthixol.
MethamphetamineZuclopenthixol may decrease the stimulatory activities of Methamphetamine.
MethotrimeprazineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethylphenidateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methylphenidate.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Zuclopenthixol.
MetyrosineZuclopenthixol may increase the sedative activities of Metyrosine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Zuclopenthixol.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Zuclopenthixol.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
MitotaneThe serum concentration of Zuclopenthixol can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Zuclopenthixol.
MorphineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Zuclopenthixol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Zuclopenthixol.
NelfinavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Nelfinavir.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Zuclopenthixol.
OctreotideOctreotide may increase the QTc-prolonging activities of Zuclopenthixol.
OrphenadrineZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ParaldehydeZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Zuclopenthixol can be decreased when it is combined with Peginterferon alfa-2b.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Zuclopenthixol.
PhendimetrazineZuclopenthixol may decrease the stimulatory activities of Phendimetrazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Zuclopenthixol.
PhenobarbitalThe serum concentration of Zuclopenthixol can be decreased when it is combined with Phenobarbital.
PhentermineZuclopenthixol may decrease the stimulatory activities of Phentermine.
PhenytoinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Phenytoin.
PosaconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Posaconazole.
Potassium ChlorideZuclopenthixol may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Zuclopenthixol.
PrimidoneThe serum concentration of Zuclopenthixol can be decreased when it is combined with Primidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Zuclopenthixol.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Zuclopenthixol.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Zuclopenthixol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zuclopenthixol.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Zuclopenthixol.
RamosetronZuclopenthixol may increase the activities of Ramosetron.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Zuclopenthixol.
RifabutinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Zuclopenthixol can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Zuclopenthixol can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Zuclopenthixol can be increased when it is combined with Ritonavir.
RivastigmineRivastigmine may increase the central neurotoxic activities of Zuclopenthixol.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Zuclopenthixol.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Zuclopenthixol.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Zuclopenthixol.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Zuclopenthixol.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Zuclopenthixol.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
SulpirideThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Zuclopenthixol.
SuvorexantZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineThe therapeutic efficacy of Zuclopenthixol can be decreased when used in combination with Tacrine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Zuclopenthixol.
TelaprevirThe serum concentration of Zuclopenthixol can be increased when it is combined with Telaprevir.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Zuclopenthixol.
ThalidomideZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
TiclopidineThe metabolism of Zuclopenthixol can be decreased when combined with Ticlopidine.
TiotropiumZuclopenthixol may increase the anticholinergic activities of Tiotropium.
TopiramateThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Zuclopenthixol.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zuclopenthixol.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Zuclopenthixol.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Zuclopenthixol.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Zuclopenthixol.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Zuclopenthixol.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Zuclopenthixol.
VerapamilThe serum concentration of Zuclopenthixol can be increased when it is combined with Verapamil.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Zuclopenthixol.
VoriconazoleThe serum concentration of Zuclopenthixol can be increased when it is combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Zuclopenthixol.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Zuclopenthixol.
ZolpidemZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food InteractionsNot Available

Targets

1. D(1A) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
D(1A) dopamine receptor P21728 Details

References:

  1. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. Pubmed
  2. Manzaneque JM, Navarro JF: An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5. Pubmed

2. D(1B) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
D(1B) dopamine receptor P21918 Details

References:

  1. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. Pubmed
  2. Manzaneque JM, Navarro JF: An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5. Pubmed

3. D(2) dopamine receptor

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
D(2) dopamine receptor P14416 Details

References:

  1. Gareri P, De Fazio P, Stilo M, Ferreri G, De Sarro G: Conventional and Atypical Antipsychotics in the Elderly : A Review. Clin Drug Investig. 2003;23(5):287-322. Pubmed
  2. Lublin H, Gerlach J, Hagert U, Meidahl B, Molbjerg C, Pedersen V, Rendtorff C, Tolvanen E: Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. Eur Neuropsychopharmacol. 1991 Dec;1(4):541-8. Pubmed
  3. Nyberg S, Farde L, Bartfai A, Halldin C: Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol. 1995 Nov;10(4):221-7. Pubmed
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

4. Alpha-1A adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-1A adrenergic receptor P35348 Details

References:

  1. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. Pubmed

5. Alpha-2A adrenergic receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Alpha-2A adrenergic receptor P08913 Details

References:

  1. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. Pubmed

6. 5-hydroxytryptamine receptor 2A

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 2A P28223 Details

References:

  1. Nyberg S, Farde L, Bartfai A, Halldin C: Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans. Int Clin Psychopharmacol. 1995 Nov;10(4):221-7. Pubmed
  2. Gjerden P, Slordal L, Bramness JG: Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. Eur J Clin Pharmacol. 2009 Jul 31. Pubmed
  3. Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62. Pubmed

7. Histamine H1 receptor

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
Histamine H1 receptor P35367 Details

References:

http://www.lundbeck.com/upload/ca/en/files/pdf/product_monograph/Clopixol_PM_MKT_ctrl_148975_13SEPT2011_CLN_eng.pdf


Enzymes

1. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on August 29, 2007 14:18 / Updated on November 24, 2014 14:45